<DOC>
	<DOCNO>NCT00808665</DOCNO>
	<brief_summary>Major lumbar spine surgery cause inflammation , soreness swell delay discharge hospital . Dexmedetomidine ( DEX ) show anti-inflammatory effect . This study evaluate whether DEX help get patient hospital fast major spine surgery reduce inflammation associate procedure . A separate part study evaluate blood level specific indicator inflammation call cytokine . Measuring cytokine surgery aid determine DEX alter inflammatory response .</brief_summary>
	<brief_title>Intraoperative Infusion Precedex Reduce Length Stay After Lumbar Spine Fusion</brief_title>
	<detailed_description>Inflammation two-edged sword , one edge essential healing , potentially delay recovery . There evidence modest attenuation initial course inflammatory response ( IR ) - essentially `` banking fire '' early IR - may benefit shorten overall hospital course . Several medication evaluated/utilized intra- perioperatively modulate different component IR , include local anesthetic , steroid non-steroidal drug . Additionally , pro-and anti-inflammatory property various alpha- beta-adrenergic agonist antagonist characterize . Of last category , dexmedetomidine ( DEX ) , highly specific ligand subtypes alpha-2 receptor throughout body , substantial potency sedation , analgesia reduction stress response wide variety surgical environment well contribute cardiovascular stability CABG open craniotomy . Additionally , DEX show quite powerful anti-inflammatory activity murine endotoxin model . DEX 's anti-inflammatory activity likely express G protein-coupled receptor ( GPCRs ) - either conformationally similar , actual `` native '' alpha-2 receptor - polymorphonuclear leukocyte , tissue macrophage , mast cell immune system cell . Through receptor , DEX may attenuate early phase IR limit immune signal release inflammatory cytokine , potentially favorably limit body 's IR injury . In present study , primary assumption ordinarily exuberant IR would invoke major spine fusion surgery . Continuous administration intravenous DEX immediately surgery might sufficiently modulate IR shorten hospital stay . Therefore , prospective , randomize , placebo-controlled , double blind fashion , plan evaluate potential perioperative infusion DEX reduce `` time-to-fitness-for-discharge '' ( generally easy mark accurate surrogate time-to-discharge ) patient undergo major 3+ level lumbar spinal fusion procedure . Additionally , cytokine marker , pain score additional pain medication requirement associate surgery measure .</detailed_description>
	<mesh_term>Spinal Stenosis</mesh_term>
	<mesh_term>Spinal Diseases</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>ASA Classification I III Scheduled Open Posterior Lumbar Fusion 3+ ( bony ) level Allergy dexmedetomidine Cardiac disease reduce ejection fraction &lt; 30 % History cirrhosis , active hepatitis attenuate hepatic function Chronic use steroid , COX2 inhibitor , alpha2 agonist , statin Current anticoagulant therapy Patients require motor evoke potential ( MEP ) monitor Positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Lumbar Fusion</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Dexmedetomidine</keyword>
	<keyword>Length Hospital Stay</keyword>
	<keyword>General Anesthesia</keyword>
	<keyword>Anti-inflammatory</keyword>
	<keyword>GPCR</keyword>
	<keyword>Cytokine</keyword>
	<keyword>Immune Response</keyword>
</DOC>